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Abstract
Adoptive transfer (AT) T-cell therapy provides significant clinical benefits in patients with advanced
melanoma. However, approaches to non-invasively visualize the persistence of transferred T cells are
lacking. We examined whether positron emission tomography (PET) can monitor the distribution of
self-antigen-specific T cells engineered to express an herpes simplex virus 1 thymidine kinase
(sr39tk) PET reporter gene. Micro-PET imaging using the sr39tk-specific substrate 9-[4-[18F]fluoro-
3-(hydroxymethyl)-butyl]guanine ([18F]FHBG) enabled the detection of transplanted T cells in
secondary lymphoid organs of recipient mice over a 3-week period. Tumor responses could be
predicted as early as 3 days following AT when a >25-fold increase of micro-PET signal in the spleen
and 2-fold increase in lymph nodes (LNs) were observed in mice receiving combined immunotherapy
versus control mice. The lower limit of detection was ;7 3 105 T cells in the spleen and 1 3 104 T cells
in LNs. Quantification of transplanted T cells in the tumor was hampered by the sr39tk-independent
trapping of [18F]FHBG within the tumor architecture. These data support the feasibility of using PET to
visualize the expansion, homing and persistence of transferred T cells. PET may have significant
clinical utility by providing the means to quantify anti-tumor T cells throughout the body and provide
early correlates for treatment efficacy.
Introduction
Recent advances in tumor immunology have led to the de-
velopment of novel immunotherapies for cancer. While clini-
cal trials using cancer vaccines have yielded low objective
response rates (1), recent approaches based on adoptive
cell transfer immunotherapy have shown significantly higher
efficacy. Rosenberg and colleagues have demonstrated par-
tial and complete responses in ;50% of patients with meta-
static melanoma treated with adoptive transfer (AT) of
ex vivo expanded autologous tumor-infiltrating lymphocytes
and a lymphodepleting host conditioning regime (2, 3). How-
ever, it remains unclear why some patients do not respond
to treatment. Potential explanations include low TCR affinity
for tumor antigens, sub-optimal in vivo expansion, failure of
adoptively transferred T cells to gain access to secondary
lymphoid organs or lack of tumor targeting. Currently, con-
ventional immune monitoring approaches to address some
of these potential rate-limiting steps involve quantitative and
functional analyses of T cells isolated from peripheral blood
or tumor biopsies (4). While these assays provide critical
data, their main limitation stems from the inability to accu-
rately reflect the dynamic changes in the distribution and
numbers of T cells in lymphoid organs and at tumor sites. In
particular, the potential for sampling error is increased in
patients with metastatic disease and/or tumor lesions that
are poorly accessible to surgical or fine needle biopsies.
There is a need for non-invasive whole-body immune moni-
toring assays that correlate and/or predict the clinical end-
points of adoptive immunotherapy trials.
The advent of molecular imaging techniques could over-
come these limitations by enabling serial and non-invasive
visualization of adoptively transferred T cells throughout the
body. Various techniques based on optical (5), nuclear (6)
or magnetic resonance (7) imaging modalities have been
used to visualize T cells in vivo. We and others have focused
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on developing positron emission tomography (PET) imaging
approaches for immune monitoring [reviewed in (8)]. PET
allows three-dimensional (3D) and quantitative measure-
ments of the tissue accumulation of probes labeled with pos-
itron emitting radioisotopes. The sensitivity of PET is in the
low nanomolar range and, unlike optical imaging modalities,
measurements of probe accumulation are minimally im-
paired by tissue absorption and scattering. Importantly, PET
studies in animal models are fully translatable to the clinic.
Clinical PET scanners have similar sensitivities to micro-PET
instruments used to image rodents. Furthermore, while their
spatial resolution is a log order less than that of pre-clinical
imaging systems, the physical size of the imaged human
subject is also several orders of magnitude larger thereby
reducing the resolution requirements.
A common thread among previous studies on PET imaging
of anti-tumor T-cell responses relates to the strong immunoge-
nicity of cancer antigens targeted in these studies (9–13). Us-
ing PET reporter gene imaging, Koehne et al. (9) visualized
the accumulation of EBV-specific T cells in EBV-positive
tumors expressing the correct HLA-restricting element but not
in EBV-negative or HLA-mismatched tumors. In a series of
studies, our group has demonstrated the capability of PET re-
porter gene imaging to monitor primary and secondary anti-tu-
mor T-cell responses to xenoantigens encoded by sarcoma-
inducing oncoretroviruses (10, 11, 13). Su et al. (14) estab-
lished a correlation between the numbers of anti-tumor T cells
specific for a model antigen and the retention of the reporter
probe measured by PET. Similarly, another recent study corre-
lated PET signal intensities over time with quantitation of trans-
duced EBV-specific T cells detected in the tumor (15). While
these studies have validated the feasibility of using PET re-
porter gene imaging for monitoring anti-tumor immunity, T-cell
responses to strong foreign or model antigens are quantita-
tively different than those against non-mutated self-antigens
more commonly expressed by human cancers of non-viral eti-
ologies. In general, such autoreactive immune responses are
of much lower magnitude than responses to foreign antigens
and are mediated by low affinity T cells that have evaded cen-
tral and peripheral tolerance induction mechanisms (16, 17).
These differences raise the question whether PET reporter
gene imaging has the required sensitivity to allow monitoring
of T-cell responses against non-mutated self-antigens that are
frequently targeted by adoptive immunotherapies in mela-
noma and other types of cancer (18).
In the current study, we used a model of adoptive immu-
notherapy against melanoma which reproduces several key
aspects of the adoptive immunotherapy clinical trials per-
formed at the National Cancer Institute (18, 19). To enable
detection of T cells following AT, we transduced these cells
with the PET reporter gene sr39tk, an optimized variant of
the herpes simplex virus 1 (HSV1) thymidine kinase (20).
Cells engineered to express sr39tk can be visualized by mi-
cro-PET using the high-affinity substrate (9-[4-[18F]fluoro-
3-(hydroxymethyl)-butyl]guanine ([18F]FHBG) (21).
The findings of the current study were 3-fold: (i) the quan-
titation of T-cell expansion in lymphoid organs as measured
by [18F]FHBG micro-PET scans at early time points following
AT was predictive of the efficacy of adoptive immunotherapy;
(ii) sr39tk-expressing melanoma-specific T cells can be seri-
ally imaged by [18F]FHBG micro-PET and (iii) the sensitivity
of [18F]FHBG PET reporter gene imaging enables detection
of very low numbers of sr39tk+ T cells present in the spleen
and lymph nodes (LNs) of treated mice. These data suggest
that the ability of non-invasive PET imaging to measure the re-
constitution, expansion and persistence of adoptively trans-
ferred T cells into patients may have significant clinical utility for
providing early predictions of treatment efficacy. PET reporter
imaging approaches can be incorporated into the design of clin-
ical trials to evaluate novel adoptive T-cell-based immunothera-
pies against melanoma and other types of cancer.
Materials and methods
Cell lines and animals
B16-F10 (B16), a murine melanoma cell line, was obtained
from the American Type Culture Collection (Rockville, MD,
USA). Stably transfected cells were cultured in DMEM
(Gibco BRL, Gaithersburg, MD, USA) supplemented with
10% FCS (Gemini, Calabasas, CA, USA). C57BL/6 and
pmel-1 mice were bred and maintained according to the
guidelines of the Department of Laboratory Animal Medicine
(DLAM) at the University of California, Los Angeles. All ani-
mal studies were carried out by using protocols that had
been approved by DLAM.
In vitro activation of pmel-1 T cells and retroviral transduction
The retroviral vector of murine stem cell virus (pMSCV) (22)
containing a 5# long terminal repeat-driven truncated version
of the sr39tk fused with super enhanced yellow fluorescent
protein (seYFP) was used to generate high-titer helper-free
retrovirus stocks prepared by transient co-transfection of
293T cells. LNs were harvested from pmel-1 mice and cultured
with IL-2 (100 Uml1) and gp10025–33 peptide (1 lg ml
1). At
48 and 72 h post-activation, the cells were spinfection with
the MSCV-sr39tk-seYFP retrovirus (;10 multiplicity of infec-
tion) and 2 lg ml1 of lipofectamine (1800 r.p.m., 120 min,
32C, Beckman CS-6R centrifuge). Upon in vitro stimulation,
pmel-1 CD8+ T cells developed an early effector phenotype
defined by activation markers such as up-regulation of
CD25 and CD69 and of lymphoid-homing molecules (partial
down-regulation of CD62L and expression of CCR7) (23).
Approximately >95% of all of the adoptively transferred cells
were CD8+/Vb13+ T cells (data not shown). seYFP was used
to monitor transduction efficiency before AT, which was
routinely >50–70%.
AT, vaccination and tumor treatment
Six- to 12-week old female C57BL/6 were injected subcuta-
neously (s.c.) with 1 3 105 B16 melanoma cells on day 8.
On day 1, lymphopenia was induced by sub-lethal irradia-
tion (500 cGy) of tumor-bearing mice. On the next day (day 0),
mice with similarly sized tumors were randomized into
groups: (i) no adoptive cell transfer therapy (ATX), (ii) ATX
of 2–5 3 106 transduced pmel-1 cells and (iii) ATX of 2–5 3
106 transduced pmel-1 cells plus gp10025–33 peptide-pulsed
dendritic cell (DC) and human IL-2 (50 000 IU intra-peritone-
ally for 3 days after each DC administration). Caliper meas-
urements of the tumors were recorded, and the tumor
volume was calculated with the formula: 4/3p 3 width radius
3 length radius 3 height radius.
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DC preparation
DCs were differentiated from bone marrow progenitor cells
obtained from C57BL/6 mice by in vitro culture in murine
granulocyte macrophage colony-stimulating factor (100 ng ml1;
Amgen, Thousand Oaks, CA, USA) and murine IL-4
(500 U ml1; R&D Systems, Minneapolis, MN, USA) as de-
scribed by Inaba (24), with minor modifications (25). DCs were
harvested as loosely adherent cells, washed twice in PBS
(Mediatech, Herndon, VA, USA) and pulsed with gp10025–33
peptide at a concentration of 10 lM in serum-free media for
90 min at room temperature. Each mouse received;106 pulsed
DCs given s.c. at 4 sites on the back.
Micro-PET/computed tomography imaging
Animals were anesthetized, injected intravenously (i.v.) with
[18F]FHBG and scanned using a FOCUS 220 micro-PET
scanner (Siemens, Knoxville, TN, USA) as described previ-
ously (20). Images were reconstructed from the scanner
data by using an iterative maximum a posteriori algorithm
(26). In the same session, mice were injected i.v. with Fenes-
tra LC contrast agent (Advanced Research Technologies,
Quebec, Canada) and computed tomography (CT) images
were acquired on a micro-CAT II instrument (Siemens). Us-
ing Amide, quantification was performed by drawing regions
of interest (ROIs) to determine the amount of [18 F]FHBG
(microcurie) present. Animals were euthanized on approxi-
mately day 3 post-AT, immediately following micro-PET imag-
ing. Spleen, LNs and tumors were harvested, scanned by
micro-PET ex vivo and then counted in a gamma counter
(Perkin Elmer).
Isolation and analysis of adoptively transferred cells
Single-cell suspensions were prepared by dissociating LNs
through a mesh cell strainer in DMEM + 5% fetal bovine se-
rum media. Single-cell suspensions of spleens were pre-
pared in media containing 1.5 mg type IV DNase (Roche,
Mannheim, Germany). RBCs were lysed with 13 PharmLyse
buffer (PharMingen, San Diego, CA, USA). Tumors were dis-
sected, minced and incubated at 37C for 1–2 h in media
containing 1.5 mg type IV DNase, 15 mg type IV collage-
nase (Gibco) and 37.5 U type V hyaluronidase (Sigma,
St Louis, MO, USA). Ficoll gradients were performed on sin-
gle-cell suspensions. Cells were mixed with a known number
of Accucount Blank Particles (Spherotech, Libertyville, IL,
USA), stained with 7AAD (Becton Dickinson) and analyzed
on a FACSCanto instrument (Becton Dickinson). Total cell
density and viability were calculated from the ratio of 7AAD
to beads using the Diva software (BD). Cells were also
stained with Vb13-FITC (BD) and CD8–PE–Cy7 (BD) to de-
termine the percentage of Vb13+ sr39tk-seYFP+ CD8
T cells. Linear regressions of the total number of Vb13+
sr39tk+ cells versus the amount of [18F]FHBG (microcurie)
present in tissues of interest were analyzed using the PRISM
software (version 4.02; GraphPad, San Diego, CA, USA).
Autoradiography and histology
Mice were anesthetized with 2% isoflurane and injected i.v.
with 500 lCi of [18F]FHBG. After 1 h, mice were sacrificed
and tumors were harvested and embedded in the optimum
cutting temperature compound (Sakura Finetek, Torrance,
CA, USA). Frozen sections (4 lm) were sliced using a micro-
tome (Leica) and exposed on BAS-TR2025 imaging screens
overnight (FujiFilm Life Science, Stamford, CT, USA). The
screens were developed a BAS-5000 phosphor imager (Fuji-
Film Life Science). Hematoxylin and eosin staining was per-
formed on the same frozen sections.
Results
[18F]FHBG PET/CT imaging enables visualization of
melanoma-specific CD8+ T cells in the spleen and LNs of
tumor-bearing mice
Pmel-1 TCR transgenic mice were used to determine
whether T-cell responses specific for tumor-expressed self-
antigens can be visualized by PET reporter gene imaging.
CD8+ T cells from these mice express a TCR specific for an
antigenic epitope derived from the unmutated melanoma/
melanocyte-associated antigen, gp100. Tumor regression
requires a combined immunotherapy protocol consisting of
AT of T cells, lymphodepletion (X-ray therapy, XRT), peptide-
pulsed DC vaccination and high-dose systemic IL-2 (full re-
gime, Fig. 1A) (19, 23, 27, 28). Omission of any of these
components compromises treatment efficacy and results in
tumor progression. In a series of four independent studies,
we confirmed the requirement for gp10025–33/DC and IL-2 to
induce regression of established B16 melanoma following
AT of pmel-1 cells (Fig. 1B).
Ex vivo-stimulated pmel-1 T cells were retrovirally trans-
duced with the PET reporter gene sr39tk to enable visualiza-
tion and tracking with PET imaging (Fig. 1A). [18F]FHBG
micro-PET images were merged with high spatial resolution
CT images to provide anatomical information. High-definition
whole-body mouse images were generated by algebraic re-
construction of collected 3D emission data (26). 3D PET
images are displayed as a measure of percent injected dose
per gram of tissue in a false color scale, with red indicating
the highest amount of radioactivity present at that location.
In mice, [18F]FHBG also accumulates non-specifically in the
gall bladder, small and large intestine as well as in the kid-
ney and bladder due to clearance of the non-phosphory-
lated probe by hepatobiliary and renal routes. To overcome
the background in the lower abdomen, a contrast agent
(Fenestra LC) was used for precise identification of the
spleen using micro-CT imaging.
Mice were imaged on day 3 post-transfer. Top panels
of Fig. 2 show representative 3D whole-body [18F]FHBG
micro-PET/CT scans of mice receiving the full regime (XRT +
AT + IL-2 + DC) or incomplete therapy (XRT + AT). We fo-
cused on three anatomical locations: spleen, LNs and the tu-
mor. [18F]FHBG signals corresponding to the spleen were
observed in mice receiving the full regime, the only therapy
leading to objective tumor responses (Fig. 1A). The
[18F]FHBG spleen signal was reproducibly observed in all
scanned animals from the full regime group (N = 37, eight
independent experiments). Eight-six percentage of mice re-
ceiving the full regime also showed [18F]FHBG accumulation
in peripheral LNs (PLNs), including the axillary, brachial and
cervical nodes (Fig. 2A, bottom panel). In contrast, none of
the mice receiving AT and lymphodepletion without
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vaccination and cytokine treatment (XRT + AT group, N = 30,
in seven independent experiments) showed detectable
[18F]FHBG accumulation in secondary lymphoid organs
(Fig. 2B, bottom panel). Therefore, at this early time point
(72 h post-transfer), [18F]FHBG micro-PET/CT detected T-cell
homing and expansion at the spleen and LNs. Quantitation
of [18F]FHBG retention in secondary lymphoid organs
allowed us to non-invasively differentiate between mice with
and without combined immunotherapy.
Non-specific accumulation of [18F]FHBG at the tumor site
As shown in the bottom panels of Fig. 2, both groups of
mice receiving full regime or incomplete therapy showed
detectable accumulation of [18F]FHBG in the B16 mela-
noma lesions. We reasoned that such signals could be
explained by two potential mechanisms. First, adoptively
transferred sr39tk+ T cells could traffic to the tumor inde-
pendently of the DC vaccination and IL-2 treatment. Sec-
ond, the signal at the tumor site could reflect sr39tk+
T-cell-independent trapping of the probe. When tumors of
mice receiving AT of sr39tk+ T cells with and without full re-
gime were dissociated, the number of Vb13+ sr39tk+ cells
present did not correlate with the [18F]FHBG signal mea-
sured (Fig. 3A and B). To further distinguish between these
two possibilities, B16 tumor-bearing mice that received
only whole-body irradiation without AT of sr39tk+ T cells
(the XRT group) were imaged. As shown in Fig. 2(C), we
observed non-specific accumulation of [18F]FHBG in the
B16 tumors from the XRT-treated group. Tumor sizes mea-
sured with calipers correlated with [18F]FHBG retention
quantified by 3D ROIs drawn around the tumor (Fig. 3C
and D). These data suggest that the [18F]FHBG signals ob-
served at the tumor site likely reflect an sr39tk+ T-cell-
independent mechanism.
We reason that four possible mechanisms could account
for the [18F]FHBG accumulation in B16 tumors: (i)
[18F]FHBG is retained in B16 cells by a transport mecha-
nism and/or enzymatic modification or slow efflux out of
the cells; (ii) [18F]FHBG is phosphorylated by an endoge-
nous kinase expressed in B16 cells; (iii) [18F]FHBG is in-
corporated in the DNA of B16 cells and (iv) the abnormal
vasculature of B16 tumors could decrease [18F]FHBG
clearance through a ‘blood pooling’ effect. To investigate
these possibilities, we performed in vitro and in vivo
experiments. Pro-B cell lines (Ba/F3) engineered to stably
express sr39tk were used as positive controls. In vitro,
B16 cells did not retain or phosphorylate [18F]FHBG after
1 h incubation (Supplementary Figure 1A and B, available
at International Immunology Online). Unlike sr39tk+ Ba/F3
and pmel T cells, which incorporated [18F]FHBG into the
DNA after 4 h, DNA incorporation of [18F]FHBG was unde-
tectable in B16 cells (Supplementary Figure 1C, available
at International Immunology Online). Mice bearing B16
and Ba/F3-sr39tk tumors were injected with [18F]FHBG
and 1 h later mice were sacrificed to isolate tumor cells. In
contrast to Ba/F3-sr39tk tumors, there was no detectable
retention, phosphorylation or DNA incorporation of
[18F]FHBG in the B16, sr39tk-negative tumors (Supplemen-
tary Figure 1D–F, available at International Immunology
Online). Non-specific probe trapping could also be
Fig. 1. Experimental design to evaluate PET reporter gene imaging in a clinically relevant model of cancer immunotherapy. C57BL/6 mice were
implanted s.c. with 1 3 105 B16 melanoma cells in the right shoulder on day 8. Mice underwent a lymphodepleting regimen on day 1. The
following day, mice received an AT of ;5 3 106 pmel-1 T cells genetically labeled with a retroviral vector co-expressing HSV1-sr39tk and seYFP.
One group of mice received additional gp10025–33/DC vaccination and high-dose IL-2 treatment. [
18F]FHBG micro-PET imaging was performed
on different days. (A) General schematic. (B) Tumor volume measurement over time in the group of mice receiving pmel-1 cells’ AT alone (XRT +
AT) and pmel-1 cells with gp10025–33/DC vaccine and high-dose IL-2 (XRT + AT + IL-2 + DC).
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explained by the particular architecture of the B16 tumors.
These tumors are highly vascularized and show areas of
blood pooling which could decrease probe clearance, as
shown by histology and autoradiography (Fig. 3E). Given
these observations, in subsequent experiments, we fo-
cused on imaging T cells in secondary lymphoid organs
which, in contrast to B16 lesions, do not show non-specific
retention of [18F]FHBG.
[18F]FHBG micro-PET/CT serial imaging detects changes
in the persistence and trafficking of adoptively transferred
T cells
Eight mice treated with the full regime were serially imaged
by [18F]FHBG micro-PET between days 1 and 21 post-AT.
As shown in Fig. 4(A), these mice received three doses of
gp10025–33/DC vaccination and systemic IL-2 treatment at
6-day intervals (red arrows, Fig. 4B) (27). The micro-
PET imaging schedule was selected based on previous
studies showing that maximal expansion of adoptively
transferred pmel-1 T cells in recipient mice can be
detected on days 5–7 post-AT in the spleen, tumor drain-
ing LNs (DLNs) and at the tumor site (29). Later time
points were included to determine if repeated DC vaccina-
tion and IL-2 treatment could induce micro-PET measur-
able changes in the distribution and/or numbers of
adoptively transferred T cells.
Following the rapid expansion of adoptively transferred
cells visualized in the spleen on day 3 post-transfer (Fig. 2A),
the [18F]FHBG signal at this site showed a slight decrease
on day 5 (data not shown). No [18F]FHBG micro-PET
spleen signals could be detected after day 8 (data not
shown). These dynamic changes in the splenic [18F]FHBG
retention could reflect the rapid initial expansion of adop-
tively transferred cells due to homeostatic proliferation in
a lymphodepleted environment with an exogenous supply
of IL-2 and/or the antigen-dependent T-cell proliferation by
gp100-pulsed DCs, followed by the contraction phase at
later time points (29). Alternatively, the loss of the
[18F]FHBG spleen signal after day 8 could indicate the
homing of the sr39tk+ T cells to LNs, the tumor site and
other organs. Accordingly, starting on day 3 post-transfer,
six out of eight mice showed significant [18F]FHBG accu-
mulation in several LN groups including axillary, brachial
and cervical (Fig. 4B and Supplementary Figure 2, avail-
able at International Immunology Online). In the remaining
two mice, detection of [18F]FHBG signals at PLNs was
delayed until day 5 (Supplementary Figure 2, available at
International Immunology Online). In contrast to the spleen
signal, the accumulation of [18F]FHBG in LN groups was
Fig. 2. [18F]FHBG micro-PET imaging of adoptively transferred T cells in spleen and LNs in mice receiving combined immunotherapy. On day
3 post-AT, mice were imaged with micro-PET/CT 60 min after i.v. injection with [18F]FHBG and Fenestra LC contrast agent. Representative
3D PET/CT images of lymphodepleted mice bearing B16 tumors receiving (A) pmel-1 T cells with gp10025–33/DC vaccine and high-dose IL-2
(XRT + AT + IL-2 + DC), (B) pmel-1 Tcells alone (XRT + AT) and (C) no treatment (XRTonly) showing the whole body (top panels) and upper body
(bottom panels) are presented. %ID/g, percent injected dose per gram of tissue; SP, spleen; GI, gastrointestinal tract; BL, bladder; B, brachial
LN; A, axillary LN; T, tumor; GB, gall bladder; E, eye.
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more sustained and could be detected beyond day 8, until
day 19. It is important to note that the patterns of
[18F]FHBG accumulation in LNs were highly variable be-
tween individual mice (Supplementary Figure 2, available
at International Immunology Online). Furthermore, we did
not observe higher [18F]FHBG accumulation in tumor DLNs
relative to contralateral LNs. This finding could indicate that
the homing/expansion of sr39tk+ T cells in PLNs reflects
systemic effects of the DC vaccination and IL-2 treatment
rather than priming of these cells in tumor DLNs by tumor-
derived antigens.
Quantification of [18F]FHBG PET signals in secondary
lymphoid organs
The experimental strategy shown in Fig. 5(A) was used to
determine whether the numbers of adoptively transferred
sr39tk+ T cells in the spleen and LNs of treated mice corre-
late with [18F]FHBG accumulation measured in vivo by
micro-PET. Immediately following whole-body micro-PET
scans, mice receiving the full regime or XRT + AT were sacri-
ficed and isolated organs were imaged by micro-PET ex
vivo. As shown in Fig. 5(B), ex vivo scans confirmed the
identity of the lymphoid organs imaged in vivo. Gamma
counter measurements were performed to more precisely
estimate the [18F]FHBG retention in isolated organs. We ob-
served increased amounts of [18F]FHBG in the spleens of
mice receiving the full regime (1.9 6 0.4 lCi) versus XRT +
AT-treated mice (0.05 6 0.01 lCi, P < 0.05). The same
pattern was detected in LNs isolated from these mice
(23.0 6 4.6 nCi for the full regime-treated mice versus
3.3 6 0.9 nCi for XRT + AT-treated mice, P < 0.05). The
in vivo micro-PET ROI-based measurements of [18F]FHBG
retention showed an excellent correlation with radioactivity
measurements of ex vivo lymphoid organs acquired by the
gamma counter, thus confirming our method to quantify the
[18F]FHBG micro-PET signals (data not shown).
Fig. 3. Non-specific [18F]FHBG accumulation and trapping in B16 tumors. (A) Tumors from the XRT + AT + IL-2 + DC and XRT + AT group were
isolated, the accumulated [18F]FHBG radioactivity counted with the gamma counter and the cells were analyzed by FACS. (B) Correlation of
in vivo [18F]FHBG retention with the number of Vb13+ sr39tk+ cells present in tumor. (C) Lymphodepleted mice bearing different B16 tumor
masses without AT of sr39tk transduced pmel-1 T cells were imaged with [18F]FHBG micro-PET. Correlation of in vivo [18F]FHBG retention at the
tumor with B16 tumor size. (D) Ratio of in vivo [18F]FHBG uptake at the tumor site versus a contralateral background region plotted against B16
tumor size suggest that the [18F]FHBG accumulation is independent of the presence of sr39tk+ cells. (E) Autoradiography and histology suggest
that areas of [18F]FHBG accumulation correspond to blood pools in the tumor.
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To determine whether the numbers of Vb13+ sr39tk+
pmel-1 T cells present in secondary lymphoid organs
correlate with the amount of [18F]FHBG detected at these
sites, we performed flow cytometric analyses on single-
cell suspensions isolated from spleen and LNs. We ob-
served higher percentages and total numbers of sr39tk+
cells expressing the Vb13+ pmel-1 TCR in the spleens
and LNs of mice treated with the full regime compared
with the XRT + AT group (Fig. 5C). ROI-based quanti-
tation of in vivo [18F]FHBG accumulation in the spleen and
LNs showed a good correlation with numbers of Vb13+
sr39tk+ cells present (Fig. 5D and E). Linear regression
analysis of spleen signals predicted the accumula-
tion of ;60 nCi of [18F]FHBG per 106 cells in a 22 mm3 vol-
ume (Fig. 5D). For LNs, these numbers were ;12.8 nCi of
[18F]FHBG per 105 cells in a 2–3 mm3 volume (Fig. 5E).
Discussion
Advantages and limitations of PET reporter gene imaging of
adoptive immunotherapy in cancer
Adoptive immunotherapies aim to overcome immunological
tolerance to cancer by transferring autologous tumor-
specific T cells expanded ex vivo. Although promising
‘proof-of-concept’ studies have been reported in recent
years, identification of suitable biomarkers of protective
T-cell anti-tumor immune responses remains a major chal-
lenge. We describe a PET reporter gene imaging approach
which allows visualization of melanoma-specific T cells fol-
lowing AT in tumor-bearing mice. The advantages of this ap-
proach are as follows: (i) the ability to sequentially monitor
adoptive immunotherapy for extended periods of time; (ii) high
sensitivity, as demonstrated by the capability to detect rare
populations of T cells at various anatomical locations and (iii)
the safety, pharmacokinetics and dosimetry of [18F]FHBG have
been studied in rats, rabbits and normal human volunteers,
and the US Food and Drug Administration has approved its
use as an investigational new drug in clinical trials (30–32).
These studies simplify the regulatory steps required to trans-
late this imaging approach from mice to cancer patients.
[18F]FHBG PET imaging of adenovirally introduced HSV1-tk
into tumors of patients with hepatocellular cancer has been
demonstrated (33, 34). Another advantage of this approach
is that HSV1-tk was originally designed for suicide gene ther-
apy of cancer. Thus, HSV1-tk would be delivered to cancer
cells and then administration of a pharmacological dose of
gancyclovir would cause death of these cells. This built-in
safety feature should prevent possible adverse effects, in-
cluding malignant transformation as a consequence of ran-
dom insertion of viral constructs and life-threatening
autoimmunity. The combination of [18F]FHBG and HSV1-
sr39tk can also be used for monitoring the distribution of stem
cells and the effects of suicide gene therapy in clinical trials.
Several clinical trials showed that HSV1-tk gene-modified
lymphocytes for allogeneic hematopoietic stem cell transplants
in leukemic patients could be detected in circulation, bone mar-
row and peripheral tissues for >12 months, while maintaining
their anti-tumor activity (35–38). However, using quantitative
PCR assays, these studies have also revealed a significant
Fig. 4. Serial [18F]FHBG micro-PET imaging of T-cell persistence at various anatomical locations in mice treated with combined immunotherapy.
(A) Time line of the imaging study. (B) Mice were imaged with micro-PET/CT 60 min after i.v. injection with [18F]FHBG. Representative 3D micro-
PET/CT images of the same mouse on different days are displayed. Red arrows indicate days that mice received gp10025–33/DC vaccine and
high-dose IL-2. A, axillary LN; B, brachial LN; C, cervical LN; T, tumor.
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incidence (in ;23% of patients) of immune responses against
HSV1-tk, leading to a decrease in the number of circulating
cells (35, 39). In contrast, it is possible that the myeloablative
chemotherapeutic regime will significantly reduce the possi-
bility of host immune responses against sr39tk+ adoptively
transferred T cells. Other options to approach the immunoge-
nicity problem are to (i) use less immunogenic HSV1-sr39tk
variants (40) or (ii) develop alternative non-immunogenic PET
reporter genes. In this context, a recent study by Ponomarev
et al. (41) proposed the use of the human thymidine kinase 2
as a potentially non-immunogenic PET reporter gene. The hu-
man norepinephrine transporter (hNET) has been recently
evaluated as a potentially non-immunogenic PET reporter
gene. Using the norepinephrine analog 124I-MIBG, Doubrovin
et al. (15) showed that as few as 104 T lymphocytes trans-
duced ex vivo with an hNET construct could be visualized by
micro-PET in vivo. The investigators used this approach to
monitor tumor infiltration by antigen-specific T lymphocytes.
The availability of 18F-labeled hNET substrates could widen
the applicability of this approach for monitoring cell-based
therapies (15). The development of novel PET probed spe-
cific for immune cells could enable direct imaging of immune
responses and therefore circumvent the use of PET reporter
genes. We have recently developed 1-(2#-deoxy-2#-18F-
fluoroarabino-furanosyl) cytosine ([18F]FAC), a novel PET im-
aging probe (42). [18F]FAC enabled visualization of lymphoid
organs such as thymus, spleen and LNs by micro-PET. The
probe was useful for imaging localized immune activation in
a mouse model of anti-tumor immunity and enabled detection
of changes in lymphoid mass in systemic autoimmunity.
Fig. 5. Ex vivo correlation of [18F]FHBG retention with numbers of Vb13+ sr39tk+ cells present in the spleen and LNs. (A) General schematic.
Mice were injected i.v. with [18F]FHBG on day 3 post-AT. Immediately after whole-body imaging, spleen and LNs were isolated, (B) imaged
ex vivo by micro-PET, counted with the gamma counter and cells were analyzed by FACS. Mice receiving partial treatment (XRT + AT) and
combined immunotherapy group (XRT + AT + IL-2 + DC) were compared. (C) Increased numbers of live Vb13+ sr39tk+ T cells in the organs of
mice from the combined immunotherapy group (XRT + AT + IL-2 + DC) compared with the XRT + AT group. Correlation of in vivo [18F]FHBG
retention with the numbers of Vb13+ sr39tk+ cells present in (D) spleen and (E) LNs.
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Another potential limitation of sr39tk PET reporter imaging is
the non-specific accumulation of the sr39tk substrate
[18F]FHBG in B16 melanoma lesions. This could complicate
the visualization of adoptively transferred T cells in the target
tissue. It is currently unclear whether the [18F]FHBG back-
ground at the tumor site represents a more general problem
or an experimental artifact specific to the B16 melanoma. We
found that the architecture of these B16 tumor lesions
includes areas of relatively large blood pools which may
cause non-specific probe trapping. In contrast to other
tumors in which [18F]FHBG slowly clears from the tumors after
2–3 h, the probe did not clear from B16 tumors during this
time frame (data not shown). Moreover, our data showed that
the trapping of [18F]FHBG is correlated with the size of the tu-
mor. This finding complicated our experiments because these
tumors quickly reach >1 cm in diameter 1–2 weeks after in-
jection of as few as 1 3 105 melanoma cells. The non-specific
retention of [18F]FHBG has not been observed in other tumors
studied by our group and others [i.e. retroviral induced rhab-
domyosarcoma and EL4 tumors (11, 13)]. A study by Penuelas
et al. (34) allowed visualization of adenoviral-mediated trans-
gene expression in the liver tumors of patients after the initial
non-specific accumulation of [18F]FHBG by hepatocytes was
cleared through the gall bladder.
The issue of potential non-specific [18F]FHBG accumula-
tion in human cancers still needs to be addressed. If such
non-specific [18F]FHBG signals are observed, then baseline
PET scans prior to adoptive therapy might be required. The
[18F]FHBG ‘background’ may be relatively constant since
tumors in patients do not grow as rapidly as the B16 tumors.
To further demonstrate the feasibility of this imaging ap-
proach, we have imaged mice with large tumors (>1 cm
diameter) before and after intratumoral injections of pmel-
sr39tk T cells. The [18F]FHBG signal in the tumor following
T-cell injection increased by 3- to 5-fold (Supplementary
Figure 3, available at International Immunology Online).
Nonetheless, our findings indicate the need to further opti-
mize existing PET reporter gene approaches by (i) develop-
ment of PET reporter genes that are less immunogenic and
potentially more sensitive than sr39tk and (ii) radiochemical
synthesis and testing of novel sr39tk substrates with lower
non-specific accumulation than FHBG.
The lower limit of detection of PET reporter gene imaging
The approach described here was sensitive to variations in
the strength of the immunotherapeutic regime and allowed
quantitative measurements of [18F]FHBG accumulation in
the spleen and LNs of treated mice. These measurements
correlated well with the numbers of sr39tk+ melanoma-specific
T cells present at these sites determined ex vivo using flow
cytometry. We observed that the lower limit of detection, de-
fined as the lowest number of sr39tk+ T cells detected by mi-
cro-PET, was dependent on the anatomical location of these
cells. In the spleen, the lower limit of detection was ;7 3
105 sr39tk+ T cells or in terms of accumulated radioactivity,
;55 nCi of [18F]FHBG. To enable detection by micro-PET, at
least ;10% of the total number of cells in the spleen had to
express the sr39tk reporter. In contrast, the limit of detection
in LNs was 1 3 104 sr39tk+ cells, corresponding to ;2–5
nCi of [18F]FHBG, or a frequency of at least ;3% of the total
number of cells. The apparent discrepancy between sensitiv-
ity parameters in spleen and LNs could be explained by the
different architecture of these secondary lymphoid organs.
Unlike LNs that consist mainly of lymphocytes, spleens con-
tain a red pulp compartment populated by macrophages
and erythrocytes and few lymphocytes. Our data indicate
a density of white blood cells in the spleen of ;0.8 3
105 mm3 compared with ;3 3 105 mm3 in a LN.
When clinical PET scanners are used to image the heart,
brain or tumors, signals from tissues of interest are typically
1.5- to 10-fold above background levels. Our data are within
this dynamic range. For example, although PET signal from
the brain striatum is typically ;3-fold over background levels
in healthy individuals, the precision of PET allows clinicians
to monitor the loss of dopaminergic neurons in Parkinson
patients (43).
While our results indicate that PET reporter gene imaging
has sufficient sensitivity to enable repeated and non-invasive
monitoring of adoptive immunotherapy in a clinically relevant
animal model, further improvements might be necessary to
fully achieve the potential of this approach. The limit of de-
tection of small animal PET scanners is related to both their
sensitivity as well as their intrinsic noise characteristics (44).
While our studies used the micro-PET Focus 220 system
(3.5% sensitivity), new instruments such as the Inveon mi-
cro-PET (Siemens) are expected to have three times larger
peak sensitivity (;10%), from purely geometrical considera-
tions. Furthermore, methods to reduce the intrinsic noise that
stems from the natural radioactivity background of the tomo-
graphs have been developed (45). Both these factors (in-
creased sensitivity and energy windowing) can be applied
simultaneously to acquisitions that are approaching the limit
of detection. It is therefore likely that future studies will en-
able imaging of a much lower number of cells than those
shown here. It is important to note that the lower limit of de-
tection is essentially the same throughout the mouse body
(surface or deep), in contrast to bioluminescence or other
optical imaging modalities. Similar improvements to enhance
sensitivity and resolution are also being performed on clini-
cal PET scanners.
PET imaging biomarkers to evaluate adoptive
immunotherapies
A critical finding of our work was that no reproducible pat-
terns of [18F]FHBG accumulation in different LNs across dif-
ferent time points and animals could be observed. While
this finding likely reflects the inherent individual variability of
T-cell responses and the need for longitudinal immune moni-
toring studies at a whole-body level, it also raises the ques-
tion of how PET reporter gene imaging can assist the
development of predictive biomarkers. Furthermore, our data
emphasize the utility of using reporter gene imaging to non-
invasively follow and further understand the variability of dis-
tribution and expansion of adoptively transferred T cells in
lymphoid organs of patients. Concerning the B16 melanoma
model, we observed that the most informative scans were
those performed at early time points following AT. Thus, mice
showing at least 2-fold increase of [18F]FHBG retention in
the spleen and LNs rejected the B16 tumors, whereas the
lack of PET probe accumulation at these sites correlated
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with tumor progression. Importantly, while [18F]FHBG micro-
PET scans at later time points (up to 3 weeks) still showed
a similar correlation, the treatment efficacy was easily
assessed after day 5 by simply measuring the tumor vol-
umes using calipers or CT imaging. Future studies are re-
quired to determine whether our findings regarding the
optimal schedule of PET reporter gene imaging for defining
predictive biomarkers can be generalized to other models
of adoptive immunotherapy.
In conclusion, PET reporter gene imaging of AT of mela-
noma-specific T cells can be used to study the in vivo dy-
namics of AT of tumor antigen-specific T cells and to define
non-invasive predictive biomarkers of treatment efficacy.
This technique is amenable to clinical translation and could
be incorporated in the next generation of clinical trials to
evaluate novel immunotherapy approaches in melanoma
and potentially other malignancies.
Supplementary data
Supplementary figures are available at International Immu-
nology Online.
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Abbreviations
AT adoptive transfer
ATX adoptive transfer treatment
CT computed tomography
3D three-dimensional
DC dendritic cell
DLAM Department of Laboratory Animal Medicine
DLN draining LN
[18F]FAC 1-(2#-deoxy-2#-18F-fluoroarabino-furanosyl) cytosine
[18F]FHBG 9-[4-[18F]fluoro-3-(hydroxymethyl)butyl]guanine
hNET human norepinephrine transporter
HSV1 herpes simplex virus 1; i.v., intravenously
LN lymph node
MSCV murine stem cell virus
PET positron emission tomography
PLN peripheral LN
ROI region of interest
seYFP super enhanced yellow fluorescent protein
sr39tk HSV1 thymidine kinase; s.c., subcutaneously
XRT X-ray therapy
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